Recent Updates — PHH

Park Ha Biological Technology Co., Ltd. announced that its reverse stock split will become effective on August 6, 2026, with trading beginning on a split-adjusted basis at market open. The company is implementing a 1-for-8 reverse split of its Class A and Class B ordinary shares, which was previously approved by shareholders and the Board of Directors in July 2026. Prior to the split, the company had approximately 18.76 million issued and outstanding shares; post-split, this will adjust to roughly 2.35 million shares. Fractional shares resulting from the transaction will be rounded up to the nearest whole share. The company's Class A ordinary shares will continue trading on Nasdaq under the symbol BYAH but with a new CUSIP number.

Park Ha Biological Technology reported unaudited financial results for the six months ended April 30, 2026. Total revenue reached $1,257,689, a 1% increase from $1,239,197 in the prior year period, driven by a 77% rise in product sales to non-franchisees. However, franchise fee revenue fell 35% to $541,584 due to a reduction in the number of franchisees from 39 to 21. The company reported a net loss of $918,282, significantly improved from a $19,835,994 net loss in the same period of 2025. This improvement was largely due to a massive decrease in general and administrative expenses, which dropped from $20,632,549 to $1,189,274 following the absence of a large share-based payment expense. The company operates in the beauty industry, developing and selling skincare products through direct sales and franchise alliances.

Park Ha Biological Technology Co., Ltd. announced on July 6, 2026, that it has successfully completed the registration process to open a cross-border store on Amazon North America. This entry into the North American market via the Amazon platform is a key component of its global expansion strategy to reach high-end consumer markets. The company operates in the biotechnology and consumer goods sector through its brand development and international expansion initiatives.

Park Ha Biological Technology Co., Ltd. issued a notice regarding an upcoming Extraordinary General Meeting and a Class A Meeting. The filing includes proxy forms for these meetings and an amended and restated Memorandum and Articles of Association. The company is a biotechnology firm based in Wuxi, China.